Details about T. Joseph Mattingly, II

Access statistics for papers by T. Joseph Mattingly, II.

Last updated 2023-11-19. Update your information in the RePEc Author Service.

Short-id: pma2817

Journal Articles

2021

1. Exploring Patient-Reported Costs Related to Hepatitis C on the Medical Crowdfunding Page GoFundMe®
   PharmacoEconomics - Open, 2021, 5, (2), 245-250
2. Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review
   The Patient: Patient-Centered Outcomes Research, 2021, 14, (5), 471-484
3. The Importance of Collaboration in Pursuit of Patient-Centered Value Assessment
   The Patient: Patient-Centered Outcomes Research, 2021, 14, (4), 381-384

2020

4. Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review
   PharmacoEconomics, 2020, 38, (9), 927-939 View citations (1)
5. Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
   PharmacoEconomics, 2020, 38, (2), 233-242 View citations (2)

2019

6. Implementing a Health Confidence Tool at Time of Discharge
   The Patient: Patient-Centered Outcomes Research, 2019, 12, (1), 163-165
7. Penicillin skin testing in methicillin-sensitive staphylococcus aureus bacteremia: A cost-effectiveness analysis
   PLOS ONE, 2019, 14, (1), 1-9
8. What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism
   The Patient: Patient-Centered Outcomes Research, 2019, 12, (6), 631-638 View citations (4)

2018

9. Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
   PharmacoEconomics, 2018, 36, (9), 1093-1099 View citations (6)

2016

10. Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?
    PharmacoEconomics, 2016, 34, (10), 1067-1070 View citations (2)